Rinvoq is a medicine that acts on the immune system (the body’s natural defences) and is used to treat: - adults with moderate to severe rheumatoid arthritis (a disease that causes inflammation of the joints) that cannot be controlled well enough with disease-modifying anti-rheumatic medicines (DMARDs) or if the patient cannot take these medicines. It can be used on its own or with methotrexate, another medicine that acts on the immune system; - adults with active psoriatic arthritis (inflammation of the joints associated with psoriasis, a disease causing red, scaly patches on the skin) that cannot be controlled well enough with DMARDs, or if the patient cannot take these medicines. Rinvoq can be used on its own or with methotrexate; - adults with active axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis, when X-ray shows the disease, and non-radiographic axial spondyloarthritis, when there are clear signs of inflammation but X-ray does not show disease. It is used when other treatments do not work well enough; - adults and children from 12 years of age with moderate to severe atopic dermatitis (also known as eczema, when the skin is itchy, red and dry) who can be treated with a medicine given by mouth or by injection; - adults with ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) or Crohn’s disease (an inflammatory disease affecting the gut). Rinvoq is used to treat moderately to severely active disease when other medicines, including biological medicines, do not or no longer work, or if the patient cannot take them. Rinvoq contains the active substance upadacitinib.
Therapeutic Indication
### Therapeutic indication Rheumatoid arthritis RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Psoriatic arthritis RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate. Axial spondyloarthritis Non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs). Ankylosing spondylitis (AS, radiographic axial spondyloarthritis) RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. Atopic dermatitis RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Ulcerative colitis RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s disease RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Therapeutic Area (MeSH)
N/AATC Code
L04AA44
ATC Item
xl 04 aa 44
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| upadacitinib | N/A | 乌帕替尼 |
EMA Name
Rinvoq
Medicine Name
Rinvoq
Aliases
N/ANo risk management plan link.
